The rare but serious risk hiding in weight-loss injections
Following a rise in reports of side effects, the U.K. has updated its guidance on weight-loss injections. U.K. updates GLP-1 guidance after rise in pancreatitis reports The U.K.'s Medicines and Healthcare Products Regulatory Agency recently updated its guidance on weight-loss injections following a rise in cases of pancreatitis . Between 2007 and October 2025, the agency received 1,296 reports of pancreatitis linked to GLP-1 drugs, with 19 fatalities. The raw numbers sound alarming, but experts urge perspective. Pancreatitis affects 0.27% to 2.2% of GLP-1 users, rare enough to be classified "uncommon." "The risk of pancreatitis with GLP-1 agonist medications is well-documented, though the incidence remains very low," explained Mir Ali, MD, a bariatric surgeon. "The increase in reported cases is likely due to the widespread use of these medications." ...
